You just read:

Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients

News provided by

Janssen Research & Development, LLC

May 30, 2015, 07:31 ET